SCHEMBL4814182

SCHEMBL4814182

CC(C)(C)OC(=O)CNC(=O)C[O]

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.42
PTPRC P08575 2/20 0.38
GAA P10253 2/20 0.37
CA12 O43570 1/20 0.37
CA2 P00918 1/20 0.37
CA14 Q9ULX7 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
DGAT1 O75907 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
CYP2D6 P10635 1/20 0.35
TET2 Q6N021 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
APLNR P35414 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2842540 0.83 MEN1 (0.43) RECQLPTPRCGAACA12CA2
SCHEMBL4814188 0.83 RECQL (0.42) RECQLPTPRCGAACA12CA2
SCHEMBL4810916 0.82 MLYCD (0.40) RECQLGAACA2TDP1DGAT1
SCHEMBL8558174 0.81 RECQL (0.50) RECQLPTPRCGAACA12CA2
SCHEMBL16761943 0.81 RECQL (0.41) RECQLPTPRCGAACA12CA2
SCHEMBL23299718 0.81 RECQL (0.41) RECQLPTPRCGAACA12CA2
SCHEMBL7376338 0.81 RECQL (0.41) RECQLPTPRCGAACA12CA2
SCHEMBL20829083 0.81 RECQL (0.41) RECQLPTPRCGAACA12CA2
SCHEMBL4742448 0.81 RECQL (0.41) RECQLPTPRCGAACA12CA2
SCHEMBL3078398 0.81 RECQL (0.41) RECQLPTPRCGAACA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7470678-B2 Diphenylazetidinone derivatives for treating disorders of the lipid metabolism ASTRAZENECA AB (SE) 2008-12-30 US disclosed
US-20050239766-A1 Diphenylazetidinone derivatives for treating disorders of the lipid metabolism ASTRAZENECA AB (SE) 2005-10-27 US disclosed
EP-1521742-A1 DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM AstraZeneca AB (SE) 2005-04-13 EP disclosed
WO-2004005247-A1 DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM ASTRAZENECA AB (SE) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239766-A1 Diphenylazetidinone derivatives for treating disorders of the lipid metabolism CYP46A1, CYP27A1, CYP7A1 RECQL 1039/4885PTPRC 3208/4885GAA 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.